Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,431
Out of 4,837 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $48.35 | +67.53% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $277.24 | -26.78% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.58 | +13,586.91% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $9.61 | +888.55% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $27.25 | -26.61% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $48.35
Upside: +67.53%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $277.24
Upside: -26.78%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.58
Upside: +13,586.91%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $9.61
Upside: +888.55%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $27.25
Upside: -26.61%